Vitality Watch

Dossier pubmed preclinical 25-jan-2026
Animal model, organoid, or cell-culture result — not yet human

Targeted delivery of senolytic drugs using macrophage membrane-camouflaged magnetic nanoparticles inhibits endplate sclerosis.

Key claim: Macrophage membrane-camouflaged magnetic nanoparticles loaded with ABT-263 dual-target and clear senescent-like macrophages in degenerating endplates of LSI mice, suppressing IL-10–driven angiogenesis–osteogenesis coupling and alleviating endplate sclerosis as a potential LBP therapy.

Abstract

INTRODUCTION: Low back pain (LBP) is a prevalent cause of disability worldwide. A crucial mechanism underlying LBP is that senescent-like macrophages induce endplate sclerosis by coupling angiogenesis-osteogenesis through IL-10. Then, the osteoclasts attract sensory innervation to perceive pain during endplate sclerosis. Therefore, targeted clearance of senescent-like macrophages is expected to be a new direction for LBP treatment. OBJECTIVES: In light of the side effects of systemic application of senolytic drugs, we propose to construct a targeted drug delivery system to accurately remove senescent-like macrophages in degenerating endplates. METHODS: In this study, iron oxide nanoparticles (FeONPs) and the senolytic drug ABT-263 were co-encapsulated in PLGA to form magnetic nanospheres (MS@ABT), then coated with macrophage membranes (MM@MS@ABT), thus a drug-loaded delivery system with improved dual targeting ability of magnetism and inflammatory microenvironments was generated. In vivo and ex vivo imaging studies demonstrated that MM@MS@ABT aggregated at the designated mouse lumbar spine instability (LSI) modeling site. RESULTS: In vivo and in vitro findings showed that senescent-like macrophages were effectively eliminated by MM@MS@ABT, thereby inhibiting the expression and secretion of IL-10 from senescent-like macrophages. This reduced CD31Emcnangiogenesis, and ultimately alleviated endplate sclerosis. CONCLUSION: Together, MM@MS@ABT exhibits a dual-targeting ability to aggregate near degenerated endplates and release senolytic drugs precisely to eliminate senescent-like macrophages in the endplates of LSI mice. It represents a potentially effective strategy for the treatment of LBP.

Why this matters

Endplate sclerosis is an under-targeted substrate of chronic low back pain, and this study pins it to a senescent-like macrophage population whose IL-10 output couples angiogenesis to pathological osteogenesis. The delivery innovation — biomimetic homotypic targeting plus magnetic steering of an established Bcl-2/Bcl-xL senolytic — is where the novelty sits; the underlying ABT-263 mechanism and the mouse LSI model remain the limiting factors for translating this into a human LBP therapy.

Source

Link

Briefing card

Targeted delivery of senolytic drugs using macrophage membrane-camouflaged magnetic nanoparticles inhibits endplate sclerosis.
Stage: preclinical · pubmed · 25-jan-2026

If you are following senolytic progress for musculoskeletal aging, this adds a preclinical delivery platform aimed at vertebral endplate sclerosis in low back pain, with no human data yet.

Macrophage membrane-camouflaged magnetic nanoparticles loaded with ABT-263 dual-target and clear senescent-like macrophages in degenerating endplates of LSI mice, suppressing IL-10–driven angiogenesis–osteogenesis coupling and alleviating endplate sclerosis as a potential LBP therapy.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.jare.2026.01.054

build build 880 · 2bcef25 · 2026-11-18